DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
News|Articles|September 17, 2026
End-to-End Commercialization Guide
Author(s)Envision Pharma
Two Labs and Riparian, both part of Envision Pharma Group, work alongside specialty pharma manufacturers at nearly every stage of commercialization — government pricing and compliance, patient support programs, specialty pharmacy selection, trade and distribution, and post-launch optimization. Each chapter of this guide was written by the experts who lead that work, drawing on real conversations with manufacturers navigating these decisions.
Advertisement
What's Inside
- How pricing pressure, the IRA, and drug price transparency laws are reshaping commercial strategy
- Why patient support has become a commercial imperative, not an operational function
- How to select and implement a specialty pharmacy partner before launch
- Where post-launch optimization breaks down — and how to connect strategy to performance
- Insights from Two Labs and Riparian experts across every stage of commercialization
- PLUS: A Pre-Launch Readiness Assessment: Click here to take it
Advertisement
Related to this article
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
An FTC settlement moved one PBM aggregator onshore, but manufacturers still lack contract-level clarity on what affiliated fees actually buy.
Simvera PSP applies queueing science so manufacturers can test the cost and patient impact of hub staffing decisions before locking them in.
Gregg Gorniak explains how AI, RFID and serialized data are helping trading partners move DSCSA compliance from a regulatory checkbox to a source of shared operational value.
As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
Pharma pricing shifts beyond PBM rebates as Medicare and cash channels reshape launches, WAC cuts and access strategies.
Advertisement
Advertisement